IMRX
Immuneering Corporation
There isn't enough reported data to score IMRX yet.
LLY
Eli Lilly and Company
LLY's fundamentals are strong: revenue grew 46% and it turned 23% of its revenue into free cash flow. At 46x earnings, it's trading in line with its usual 48x. Analysts expect that strong growth to continue.
IMRX Fundamentals
| Metric | Status |
|---|---|
| Weak | |
| Weak | |
| Unavailable | |
| Unavailable |
IMRX's revenue and profitability are currently weak. There isn't enough data to rate its cash flow and balance sheet.
LLY Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Strong | |
| Healthy |
LLY's revenue, profitability, cash flow and balance sheet are all currently healthy.
IMRX PE Valuation
IMRX has no meaningful PE right now: it lost money over the past year.
LLY PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 27x | $845 | -41% |
| Forward | 30x | $1,427 | — |
| Current | 46x | $1,427 | — |
| Fair | 48x | $1,466 | +2.7% |
| Expensive | 85x | $2,612 | +83% |
Historical ranges are pointers, not guarantees.
LLY's PE is in its fair range at 46x. If earnings grow as analysts expect, today's price would be 30x next year's earnings, in its cheap range.
IMRX Forward outlook
There aren't enough analyst estimates for IMRX to show an outlook.
LLY Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for LLY, with profitability improving.
IMRX Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$1.14 | +$0.65 |
| Q2 2026 | -$1.15 | +$0.75 |
| Q1 2026 | -$1.28 | +$0.69 |
| Q4 2025 | -$1.49 | +$0.55 |
| Q3 2025 | -$1.79 | +$0.17 |
| Q2 2025 | -$1.90 | $0.00 |
| Q1 2025 | -$1.97 | -$0.11 |
| Q4 2024 | -$2.04 | -$0.16 |
IMRX is still losing money, but far less than before: $1.14 per share over the past year, against $2.97 at its worst in late 2021.
LLY Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $46.82 | +52% |
| Q3 2026 | $30.81 | +51% |
| Q2 2026 | $29.80 | +95% |
| Q1 2026 | $28.15 | +129% |
| Q4 2025 | $22.95 | +96% |
| Q3 2025 | $20.44 | +121% |
| Q2 2025 | $15.30 | +88% |
| Q1 2025 | $12.29 | +81% |
| Q4 2024 | $11.71 | +102% |
LLY has the edge over IMRX on earnings quality, reporting a profit while its opponent remains loss making.
IMRX Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q4 2022 | $455 | -100% |
| Q3 2022 | $38.4K | -92% |
| Q2 2022 | $94.4K | -86% |
| Q1 2022 | $183.7K | -75% |
| Q4 2021 | $189.6K | -71% |
| Q3 2021 | $482.1K | -29% |
| Q2 2021 | $660K | +37% |
| Q1 2021 | $748.2K | +55% |
LLY has the stronger quarterly revenue trend. Revenue is down 100% for IMRX versus up 39% for LLY.
| Quarter | Margin | YoY |
|---|---|---|
| Q4 2022 | -3073628% | -3067765 points |
| Q3 2022 | -34362% | -32590 points |
| Q2 2022 | -12334% | -11124 points |
| Q1 2022 | -7036% | -6203 points |
| Q4 2021 | -5863% | -4986 points |
| Q3 2021 | -1772% | -1127 points |
| Q2 2021 | -1211% | -461 points |
| Q1 2021 | -833% | -163 points |
IMRX's operating margin was −3073628% last quarter, down 3067765 points from the same quarter a year ago, near the bottom of its range since 2020.
LLY Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $24.4B | +39% |
| Q2 2026 | $23B | +48% |
| Q1 2026 | $19.8B | +56% |
| Q4 2025 | $19.3B | +43% |
| Q3 2025 | $17.6B | +54% |
| Q2 2025 | $15.6B | +38% |
| Q1 2025 | $12.7B | +45% |
| Q4 2024 | $13.5B | +45% |
LLY's revenue has grown year over year for 14 quarters in a row: $24.4B last quarter, up 39% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 34% | -6.6 points |
| Q2 2026 | 40% | -3.3 points |
| Q1 2026 | 45% | +18 points |
| Q4 2025 | 43% | +5.6 points |
| Q3 2025 | 41% | +27 points |
| Q2 2025 | 44% | +12 points |
| Q1 2025 | 27% | -1.8 points |
| Q4 2024 | 37% | +10 points |
LLY's operating margin was 34% last quarter, down 6.6 points from the same quarter a year ago.
IMRX Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$16.8M | -$4.8M |
| Q2 2026 | -$16.5M | -$7.1M |
| Q1 2026 | -$18.5M | -$4.4M |
| Q4 2025 | -$10M | +$4.6M |
| Q3 2025 | -$12M | +$1.5M |
| Q2 2025 | -$9.4M | +$2.1M |
| Q1 2025 | -$14.1M | +$1.4M |
| Q4 2024 | -$14.5M | -$2.6M |
IMRX has burned cash in almost every quarter: −$62M over the past year, against −$50M the year before.
LLY Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $8.2B | +22% |
| Q2 2026 | $7.8B | +458% |
| Q1 2026 | $3B | +1826% |
| Q4 2025 | $677.9M | -31% |
| Q3 2025 | $6.7B | +186% |
| Q2 2025 | $1.4B | +476% |
| Q1 2025 | $156.1M | -13% |
| Q4 2024 | $977.8M | +$2.4B |
LLY has the edge over IMRX on cash generation, producing positive trailing cash flow while its opponent burns cash.
IMRX Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | +17K shares |
| 1 year | +63% | +25M shares |
| 3 years | +121% | +35.4M shares |
| 5 years | +1206% | +59.8M shares |
| Available history | +379% | +51.2M shares |
IMRX has 65M diluted shares, up 63% from a year ago.
| Quarter | Spent |
|---|---|
| Q1 2021 | — |
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
LLY Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | -300K shares |
| 1 year | -0.6% | -5.4M shares |
| 3 years | -0.7% | -6.4M shares |
| 5 years | -1.9% | -17.4M shares |
| Available history | -4.5% | -42.3M shares |
LLY has the edge over IMRX on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $377M |
| Q2 2026 | $1.6B |
| Q1 2026 | $2.4B |
| Q4 2025 | $1.5B |
| Q3 2025 | $708.1M |
| Q2 2025 | $692.2M |
| Q1 2025 | $1.2B |
| Q4 2024 | $2.1B |
LLY spent $5.8B buying back its own shares over the past year, up 26% from the year before.
IMRX Net Leverage
IMRX's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
LLY Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.2x | Healthy |
| Q2 2026 | 1.3x | Healthy |
| Q1 2026 | 1.2x | Healthy |
| Q4 2025 | 1.3x | Healthy |
| Q3 2025 | 1.3x | Healthy |
| Q2 2025 | 2.0x | Healthy |
| Q1 2025 | 2.3x | Moderate |
| Q4 2024 | 2.1x | Moderate |
LLY's net debt is about 1.2 years of its operating earnings (EBITDA), about the same as a year ago.
IMRX Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 38.9 | Neutral |
| Stochastic | 16.4 | Oversold |
IMRX's weekly RSI is 39 (neutral) and its Stochastic is 16 (oversold).
LLY Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 68.3 | Neutral |
| Stochastic | 84.1 | Overbought |
LLY's weekly RSI is 68 (neutral) and its Stochastic is 84 (overbought).
IMRX PE vs Healthcare Sector
IMRX has no meaningful PE right now: it lost money over the past year.
LLY PE vs Healthcare Sector
| Metric | LLY | Sector median | Relative |
|---|---|---|---|
| PE | 46x | 26x | 79% above |
| PE % | 48 | 29 | 19 pts above |
LLY is trading at 46x earnings, a 79% premium to the Healthcare sector's median of 26x.
IMRX Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $3.84 | 4.4% below |
| 20 week MA | $4.38 | 16% below |
| 50 week MA | $4.91 | 25% below |
| 100 week MA | $4.24 | 13% below |
| 200 week MA | $4.78 | 23% below |
IMRX is in a downtrend: it's below all five of its weekly moving averages, and 23% below its 200-week average.
LLY Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1,279.4 | 12% above |
| 20 week MA | $1,218.8 | 17% above |
| 50 week MA | $1,102.2 | 29% above |
| 100 week MA | $954.1 | 50% above |
| 200 week MA | $797.5 | 79% above |
LLY has the edge over IMRX on trend strength, trading above more of its moving averages.
IMRX Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $17.6 | $20.5 | +17% |
| 2022 | $20.5 | $4.37 | -79% |
| 2023 | $4.37 | $7.35 | +68% |
| 2024 | $7.35 | $2.33 | -68% |
| 2025 | $2.33 | $6.73 | +189% |
| 2026 YTD | $6.73 | $3.67 | -45% |
IMRX's yearly returns have swung widely, from +189% in 2025 to −79% in 2022. It's down 45% so far in 2026.
LLY Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $131.5 | $166.7 | +27% |
| 2021 | $166.7 | $273.1 | +64% |
| 2022 | $273.1 | $367.9 | +35% |
| 2023 | $367.9 | $582.9 | +58% |
| 2024 | $582.9 | $783.2 | +34% |
| 2025 | $783.2 | $1,077.8 | +38% |
| 2026 YTD | $1,077.8 | $1,427.3 | +32% |
LLY has the edge over IMRX on returns for 2026, with the stronger performance.